Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A

@article{Tiede2016ProphylaxisVO,
  title={Prophylaxis vs. on‐demand treatment with Nuwiq® (Human‐cl rhFVIII) in adults with severe haemophilia A},
  author={A. Tiede and J. Oldenburg and T. Lissitchkov and S. Knaub and J. Bichler and M. Manco-Johnson},
  journal={Haemophilia},
  year={2016},
  volume={22}
}
  • A. Tiede, J. Oldenburg, +3 authors M. Manco-Johnson
  • Published 2016
  • Medicine
  • Haemophilia
  • Haemophilia A is treated with FVIII, either prophylactically or on demand. Prophylaxis is the gold standard in children and evidence is accumulating in adults. 
    26 Citations

    Topics from this paper.

    PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
    • 19
    Efficacy and safety of Nuwiq® (human‐cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures
    • 5
    Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries
    Emicizumab: Review of the literature and critical appraisal
    • 12
    The availability of new drugs for hemophilia treatment

    References

    SHOWING 1-10 OF 35 REFERENCES
    Novel, human cell line‐derived recombinant factor VIII (human‐cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety
    • 27
    Prophylaxis in haemophilia should be life-long.
    • M. Makris
    • Medicine
    • Blood transfusion = Trasfusione del sangue
    • 2012
    • 61
    Treatment of hemophilia: a review of current advances and ongoing issues
    • 72
    • PDF
    The first recombinant FVIII produced in human cells – an update on its clinical development programme
    • 33
    Guidelines for the management of hemophilia
    • 1,299
    • PDF
    European Study on Orthopaedic Status of haemophilia patients with inhibitors
    • 172
    Effects of secondary prophylaxis started in adolescent and adult haemophiliacs
    • 111